Delamanid: Extension study data

Data from 421 MDR-TB patients in the open-label Study 242-10-116 extension of the double-blind, international Phase IIb 242-07-204 trial showed that 75% of patients who received delamanid for >=6 months were classified as having "favorable outcomes" vs. 55% of patients who received delamanid for <=2 months (p<0.001). All patients received a standard background regimen for multidrug-resistant TB as recommended by the World Health Organization. Researchers classified the favorable outcome group as patients who were cured or completed treatment, while the unfavorable outcome group comprised patients who failed treatment course, defaulted or died. Additionally, there were 2 deaths in the >=6-month delamanid group vs. 19 deaths in the <=2-month delamanid group. In a subset of patients with extremely drug-resistant TB (XDR-TB), favorable outcomes occurred in 61.4% of patients on long-term delamanid treatment vs. 50% of patients on short-term delamanid treatment. Data were published in the European Respiratory Journal. ...